Contact information
Sarah Kelly
MSc
Clinical Programme Director (Global)
Leading and managing the clinical research portfolio across low- and middle-income countries, overseeing programme delivery, team leadership, and operational strategy focused on vaccine-preventable diseases
My interests lie in Global Health and vaccines, with a focus on leading and managing the clinical research portfolio across low- and middle-income countries. I have responsibility for the planning, implementation, delivery and oversight of clinical trials and research studies, focusing on vaccine-preventable diseases. As a registered nurse with an emergency room background and experience with Médecins Sans Frontières in West Africa, I bring hands-on clinical and operational expertise. Since joining the Oxford Vaccine Group in 2006, I have contributed to industry and non-industry trials across the UK, Southeast Asia, Africa, and Latin America, and continue to provide guidance and support to clinical teams both in the UK and internationally
Recent publications
-
Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
Kandasamy R. et al, (2024), Vaccine, 42, 4066 - 4071
-
Evaluation of Acute and Convalescent Antibody Concentration Against Pneumococcal Capsular Polysaccharides for the Diagnosis of Pneumococcal Infection in Children with Community-Acquired Pneumonia
Carter MJ. et al, (2024), Pediatric Infectious Disease Journal, 43, E67 - E70
-
Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Shakya M. et al, (2019), N Engl J Med, 381, 2209 - 2218